Isotretinoin

Isotretinoin's association with extremely high rates of severe congenital birth defects when taken during pregnancy led to the creation of one of the strictest prescription tracking systems in global pharmaceutical history. The iPLEDGE program mandates registration, mandatory risk education, and monthly negative pregnancy tests for all people of childbearing potential before dispensing, establishing a widely referenced model for managing other teratogenic prescription medications later approved for the market.

Unlike other acne treatments that only suppress symptoms temporarily, a single standard 15 to 20 week isotretinoin course delivers long-term or permanent clearance of severe acne for roughly 80% of patients. For patients facing permanent facial scarring and associated high rates of depression, social anxiety and low self-esteem tied to disfiguring acne, the drug has been described as life-changing by large global patient communities.

Despite rigorous clinical trial data confirming its core safety profile when used as directed, isotretinoin has remained the subject of decades of public controversy over unconfirmed links to mood disorders, inflammatory bowel disease, and other long-term adverse effects. These unproven claims have at times reduced appropriate access to the medication for eligible patients, creating ongoing tension between dermatology clinical bodies and public perceptions of drug risks.